AU2003258081A8 - Cancer vaccines containing epitopes of oncofetal antigen - Google Patents

Cancer vaccines containing epitopes of oncofetal antigen

Info

Publication number
AU2003258081A8
AU2003258081A8 AU2003258081A AU2003258081A AU2003258081A8 AU 2003258081 A8 AU2003258081 A8 AU 2003258081A8 AU 2003258081 A AU2003258081 A AU 2003258081A AU 2003258081 A AU2003258081 A AU 2003258081A AU 2003258081 A8 AU2003258081 A8 AU 2003258081A8
Authority
AU
Australia
Prior art keywords
cancer vaccines
vaccines containing
oncofetal antigen
containing epitopes
epitopes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
AU2003258081A
Other versions
AU2003258081A1 (en
Inventor
Joseph H Coggin Jr
Adel L Barsoum
James W Rohrer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
South Alabama Medical Science Foundation
Original Assignee
South Alabama Medical Science Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by South Alabama Medical Science Foundation filed Critical South Alabama Medical Science Foundation
Publication of AU2003258081A1 publication Critical patent/AU2003258081A1/en
Publication of AU2003258081A8 publication Critical patent/AU2003258081A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Dispersion Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2003258081A 2002-08-02 2003-08-04 Cancer vaccines containing epitopes of oncofetal antigen Abandoned AU2003258081A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40085102P 2002-08-02 2002-08-02
US60/400,851 2002-08-02
PCT/US2003/024518 WO2004012681A2 (en) 2002-08-02 2003-08-04 Cancer vaccines containing epitopes of oncofetal antigen

Publications (2)

Publication Number Publication Date
AU2003258081A1 AU2003258081A1 (en) 2004-02-23
AU2003258081A8 true AU2003258081A8 (en) 2004-02-23

Family

ID=31495892

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003258081A Abandoned AU2003258081A1 (en) 2002-08-02 2003-08-04 Cancer vaccines containing epitopes of oncofetal antigen

Country Status (6)

Country Link
US (2) US7718762B2 (en)
EP (1) EP1538900B1 (en)
AU (1) AU2003258081A1 (en)
CA (1) CA2492938C (en)
ES (1) ES2565578T3 (en)
WO (1) WO2004012681A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080286312A1 (en) * 2002-06-12 2008-11-20 Gavish-Galilee Bio Applications Ltd. Membrane-anchored beta2 microglobulincovalently linked to MHC class I peptide epitopes
US20060003315A1 (en) * 2002-06-12 2006-01-05 Gavish-Galilee Bio Applications Ltd. Membrane-anchored beta2 microglobulin covalently linked to mhc class 1 peptide epitopes
DE60218173T2 (en) 2002-10-11 2007-11-22 Sentoclone Ab Immunotherapy for cancer
WO2006014579A2 (en) * 2004-07-08 2006-02-09 The Regents Of California Enhancing class i antigen presentation with synthetic sequences
ES2367643T3 (en) * 2005-04-26 2011-11-07 Immatics Biotechnologies Gmbh IDENTIFIER OF AN EPYTHOPE OF T-LYMPHOCYTES PRESENTED BY THE ANTIGEN HLA-A2 AND DERIVED FROM THE PROTEIN OF THE IMMATURE LAMININE RECEIVER OF THE ONCOFETAL ANTIGEN AND USES OF THIS.
US8101173B2 (en) 2005-12-21 2012-01-24 Sentoclone International Ab Method for treating urinary bladder cancer
WO2007071390A1 (en) 2005-12-21 2007-06-28 Sentoclone Ab Method for treating malignant melanoma
EP1966370B1 (en) 2005-12-21 2013-02-20 SentoClone International AB Method for obtaining T-lymphocytes
EP1966369B1 (en) 2005-12-21 2010-10-06 Sentoclone AB Method for expansion of tumour-reactive t-lymphocytes for immunotherapy of patients with cancer
EP1981533A1 (en) * 2006-02-06 2008-10-22 Medizinische Universität Wien Vaccine and antigen mimotopes against cancerous diseases associated with the carcinoembryonic antigen cea
CA2597840A1 (en) * 2006-09-01 2008-03-01 Government Of The United States Of America, As Represented By The Secret Ary, Department Of Health And Human Services Methods and compositions for the treatment and prevention of cancer
WO2010111669A1 (en) * 2009-03-26 2010-09-30 Quantum Immunologics, Inc. Oncofetal antigen/immature laminin receptor peptides for the sensitization of dendritic cells for cancer therapy
CN102574925A (en) * 2009-03-26 2012-07-11 昆腾免疫有限公司 Oncofetal antigen/immature laminin receptor antibodies for diagnostic and clinical applications
US20130052211A1 (en) * 2009-07-09 2013-02-28 South Alabama Medical Science Vaccines with oncofetal antigen/ilrp-loaded autologous dendritic cells and uses thereof
EP2330122A1 (en) * 2009-12-02 2011-06-08 Asklepios Kliniken Hamburg Gmbh OFA/iLRP derived modified peptide
EP2697386B1 (en) 2011-04-08 2017-11-01 Tufts Medical Center, Inc. Pepducin design and use
GB201519557D0 (en) * 2015-11-05 2015-12-23 Univ Witwatersrand Jhb Compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions
WO2017083618A1 (en) 2015-11-13 2017-05-18 Oasis Pharmaceuticals, LLC Protease-activated receptor-2 modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69739423D1 (en) * 1996-04-05 2009-07-09 Univ South Alabama USE OF ONKOFÖTAL-ANTIGEN SPECIFIC CD4, CD8 CYTOTOXIC, SUPPRESSOR T CELLS AND INTERLEUKIN-10
US6080725A (en) * 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
WO1998053048A1 (en) * 1997-05-21 1998-11-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods and compositions for making dendritic cells from expanded populations of monocytes and for activating t cells
US6602510B1 (en) * 2000-04-05 2003-08-05 Epimmune Inc. HLA class I A2 tumor associated antigen peptides and vaccine compositions
DE10041515A1 (en) * 2000-08-24 2002-03-14 Gerold Schuler Process for the production of ready-to-use, antigen-loaded or unloaded, cryopreserved mature dendritic cells
US7118753B2 (en) * 2002-02-08 2006-10-10 Anawrahta Biotech Co., Ltd. Enhancing cell-based immunotherapy
US20040001847A1 (en) * 2002-06-26 2004-01-01 Lasalvia-Prisco Eduardo M. Method and composition to elicit an effective autologous antitumoral immune response in a patient
ES2367643T3 (en) * 2005-04-26 2011-11-07 Immatics Biotechnologies Gmbh IDENTIFIER OF AN EPYTHOPE OF T-LYMPHOCYTES PRESENTED BY THE ANTIGEN HLA-A2 AND DERIVED FROM THE PROTEIN OF THE IMMATURE LAMININE RECEIVER OF THE ONCOFETAL ANTIGEN AND USES OF THIS.

Also Published As

Publication number Publication date
WO2004012681A2 (en) 2004-02-12
EP1538900A2 (en) 2005-06-15
US20060165709A1 (en) 2006-07-27
WO2004012681A3 (en) 2004-11-11
US8709405B2 (en) 2014-04-29
AU2003258081A1 (en) 2004-02-23
CA2492938A1 (en) 2004-02-12
EP1538900A4 (en) 2008-09-24
US20100183643A1 (en) 2010-07-22
US7718762B2 (en) 2010-05-18
EP1538900B1 (en) 2016-01-06
CA2492938C (en) 2012-05-22
ES2565578T3 (en) 2016-04-05

Similar Documents

Publication Publication Date Title
AU2003258081A8 (en) Cancer vaccines containing epitopes of oncofetal antigen
EP1633785A4 (en) Human monoclonal antibodies against bacillusanthracis protective antigen
IL210378A0 (en) Tumor associated antigen, peptides thereof, and use of same as ati-tumor vaccines
SI1620456T1 (en) Hla-a2 tumor associated antigen peptides and compositions
TWI347951B (en) Therapeutic human anti-il-1r1 monoclonal antibody
EP1461082A4 (en) Antibodies against carboxic anhydrase ix (ca ix) tumor antigen
EP1546324A4 (en) Expression vectors encoding epitopes of target-associated antigens
IL172242A0 (en) Antibodies specific for cancer associated antigen sm5-1 and uses thereof
AU2003270369A8 (en) Minimally immunogenic variants of humanized col-1 antibody against carcinoembryonic antigen
EP1550453A4 (en) Cancer antigen peptide preparation
EP1572090A4 (en) Cancer vaccine containing cross-species epitopes of telomerase reverse transcriptase
AU2003207459A8 (en) Cancer-associated epitope
EP1462456A4 (en) Tumor antigens
AU2003292405A8 (en) Cancer immunotherapy using polycomb proteins
EP1667701A4 (en) Tumor vaccine
PL356770A1 (en) Use of anti-idiotypical antibodies as vaccines against cancer
AU2003294220A8 (en) Ii-key/antigenic epitope hybrid peptide vaccines
KR100700323B1 (en) Antibody fragments specific for human carcinoembryonic antigen cea
AU2003203140A8 (en) Immunogenic carcinoembryonic antigen (cea)
AU2003255544A8 (en) Tumor specific oligosaccharide epitopes and use thereof
PL371202A1 (en) Anti-idiotype anti-cea antibody molecules and its use as cancer vaccine
EP1454914A4 (en) Tumor antigen
AU2003219983A8 (en) Immunotherapy for prostate cancer using recombinant bacille calmette-guerin expressing prostate specific antigens
AU2003268180A8 (en) Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix
EP1403283A4 (en) Tumor antigen

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase